{"prompt": "['2016N298481_0', 'CONFIDENTIAL', '205270', '12.3.3.', 'Evaluating AEs and SAEs', 'Assessment of Intensity', 'The investigator will make an assessment of intensity for each AE and SAE reported', 'during the study and will assign it to one of the following categories:', 'Mild: An event that is easily tolerated by the participant, causing minimal', 'discomfort and not interfering with everyday activities.', 'Moderate: An event that is sufficiently discomforting to interfere with normal', 'everyday activities', 'Severe: An event that prevents normal everyday activities. An AE that is assessed as', 'severe will not be confused with an SAE. Severity is a category utilized for rating the', 'intensity of an event; and both AEs and SAEs can be assessed as severe.', 'An event is defined as \"serious\\' when it meets at least one of the pre-defined', 'outcomes as described in the definition of an SAE.', 'Assessment of Causality', 'The investigator is obligated to assess the relationship between randomized treatment', 'and the occurrence of each AE/SAE.', 'A \"reasonable possibility\" is meant to convey that there are facts/evidence or', 'arguments to suggest a causal relationship, rather than a relationship cannot be ruled', 'out.', 'The investigator will use clinical judgment to determine the relationship.', 'Alternative causes, such as natural history of the underlying diseases, concomitant', 'therapy, other risk factors, and the temporal relationship of the event to the or', 'randomized treatment will be considered and investigated.', 'The investigator will also consult the IB and/or Product Information, for marketed', 'products, in the determination of his/her assessment.', 'For each AE/SAE the investigator must document in the medical notes that he/she', 'has reviewed the AE/SAE and has provided an assessment of causality.', 'There may be situations when an SAE has occurred and the investigator has minimal', 'information to include in the initial report to GSK. However, it is very important', 'that the investigator always make an assessment of causality for every event', 'prior to the initial transmission of the SAE data to GSK.', 'The investigator may change his/her opinion of causality in light of follow-up', 'information, amending the SAE data collection tool accordingly.', 'The causality assessment is one of the criteria used when determining regulatory', 'reporting requirements.', '87']['2016N298481_02', 'CONFIDENTIAL', '205270', 'Follow-up of AEs and SAEs', 'The investigator is obligated to perform or arrange for the conduct of supplemental', 'measurements and/or evaluations as may be indicated or as requested by GSK to', 'elucidate as fully as possible the nature and/or causality of the AE or SAE.', 'The investigator is obligated to assist. This may include additional laboratory tests', 'or investigations, histopathological examinations or consultation with other health', 'care professionals.', 'New or updated information will be recorded in the originally completed eCRF.', 'The investigator will submit any updated SAE data to GSK within the designated', 'reporting time frames.', '88']['2016N298481_02', 'CONFIDENTIAL', '205270', '12.4.', 'Appendix 4: Female Eligibility Criteria, Contraceptive', 'Guidance and Collection of Pregnancy Information', 'Woman of Childbearing Potential (WOCBP)', 'A woman is considered fertile following menarche and until becoming post-', 'menopausal unless permanently sterile (see below)', 'A female subject is eligible to participate if she is not pregnant (as confirmed by a', 'negative urine FRP test for females of reproductive potential only), not', 'breastfeeding, or at least one of the following conditions applies:', 'Reproductive potential and agrees to follow one of the options listed in the', 'List of Highly Effective Contraceptive Methods (Table 9) in WOCBP', 'from 30 days prior to the first dose of randomized treatment and until', 'completion of the Follow-up visit (4-6 weeks after the end of randomized', 'treatment); those who permanently discontinue randomized treatment', 'prior to the end of the study should continue contraceptive methods', 'following the Early Treatment Discontinuation Visit until the final', 'pregnancy test assessment at a subsequent study visit (at least 4 weeks', 'after the end of randomized treatment) as described in the SoA (Section 2)', 'Women in the following categories are not considered WOCBP', 'Premenarchal', 'Premenopausal female with ONE of the following:', 'Documented hysterectomy', 'Documented bilateral salpingectomy', 'Documented bilateral oophorectomy', 'Documented tubal ligation', \"Note: Documentation can come from the site personnel's: review of participant's\", 'medical records, medical examination, or medical history interview.', 'Postmenopausal female', 'Postmenopausal defined as 12 months of spontaneous amenorrhea. In', 'questionable cases, a blood sample with simultaneous FSH and estradiol', 'consistent with menopause is confirmatory >23 MIU/mL (23 IU/L) and estradiol', '<10 pg/mL (or <37 pmol/L) is confirmatory). Females on hormone replacement', 'therapy (HRT) and whose menopausal status is in doubt will be required to use', 'one of the highly effective contraception methods if they wish to continue their', 'HRT during the study. Otherwise, they must discontinue HRT to allow', 'confirmation of post-menopausal status prior to study enrollment.', '89']\n\n###\n\n", "completion": "END"}